Business Wire

CT-WELLAIR

23.3.2022 07:35:03 CET | Business Wire | Press release

Share
WellAir Launches a New Advanced Air Cleaning Device in Europe with Independently Tested Industry Leading 99.9% Effectiveness Against Airborne Pathogens

WellAir, the leading health technology company that provides indoor air disinfection solutions, today announced the European launch of its Novaerus Defend 400. Novaerus has been a pioneer in combatting airborne and surface transmitted hospital-acquired infections world-wide for over 10 years. The air cleaning device is CE marked and is 99.9% effective at inactivating airborne pathogens such as SARS-CoV-2 proxy virus (MS2 Bacteriophage), MRSA, bacteria, and fungi; while also purifying the air of particulate matter, volatile organic compounds, gases, and odours. With the launch, WellAir continues to chart a new path forward for healthy indoor environments at a time when air quality has never been a bigger priority.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005036/en/

Recent research published in the Journal of Hospital Infectionalso found that Novaerus air disinfection devices utilizing NanoStrike technology - a transformational method of air disinfection that bursts airborne pathogen cells, rapidly inactivating them to help ensure they are no longer a threat of infection - may contribute to the prevention of hospital-acquired infections by reducing the microbial load in the air. The study is the first of its kind to examine portable air cleaning and disinfection devices in an intensive care unit.

“We are bringing the Defend 400 to the European market at a turning point for indoor air quality, as more people are recognizing the role it plays in health and wellness,” said WellAir Chief Science Officer Felipe Soberon. “Given that much of this technology was developed in Dublin laboratories, it is great to see this technology now available in Europe, following a successful U.S. launch.”

Unlike other air cleaning technologies, NanoStrike’s effectiveness lies in its ability to inactivate nanosized pathogens on contact. The Defend 400’s four-stage pathogen inactivation and filtration process also utilizes medical-grade filters in order to capture bacterial debris, fine and large particles, VOCs, gases, odours, and impurities.

“COVID-19 has focused more attention on indoor air quality and has elevated the importance of safer indoor environments by reducing the risk of exposure to airborne pathogens. This is exactly what the Defend 400 is designed to do”, said WellAir President and CEO Todd M. Pope. “This portable device expands our product portfolio, delivering powerful air cleaning in multiple device sizes.”

The Novaerus Defend 400 is ideally suited for healthcare settings but is effective in a wide array of indoor environments, such as schools and offices. It is available through WellAir’s Novaerus global distributor network. For more information, visit: https://www.novaerus.com/novaerus-defend-400.

About WellAir

WellAir’s mission is to make the indoor world cleaner and safer. The company’s broad range of clean air and surface products are scientifically proven to help safeguard how people work, live and play. WellAir, headquartered in Dublin, Ireland, with offices in Research Triangle Park, North Carolina, and Stamford, Connecticut, is a leading provider of infection control solutions.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plural Raises €1bn to Back the Frontier Founders Building a New Europe16.11.2026 10:00:00 CET | Press release

Plural’s largest raise to date: almost four times its €260m inaugural fund in 2022, and double its €500m second fund in 2024 All former founders and operators, Plural’s partners back founders early to build generational companies that compete globally from Europe Plural’s companies have raised over €3bn in follow-on capital in the last twelve months alone as European tech accelerates Plural, the early-stage investment fund led by founders and operators, has raised €1bn to back the founders Europe is counting on. Plural’s ambition is to have GDP-level impact on Europe. It backs founders building what a changing world needs most over the next decade: energy, AI infrastructure, defence, health and other frontier technologies. For two decades, the bulk of the world’s most valuable technology companies have been built in the US and China, leaving Europe a customer rather than a creator. That has cost the continent prosperity and bargaining power. Rapid technological change now gives Europe

SES and ITU Expand Partner2Connect Digital-learning Initiative to 30 African Schools16.11.2026 09:36:00 CET | Press release

Initiative in Malawi, Burundi, Zambia and Zimbabwe will leverage SES satellite solutions to extend digital learning opportunities to 20,000-30,000 students and teachers. SES, a leading space solutions company, announced progress on its commitment to the International Telecommunication Union's (ITU) Partner2Connect Digital Coalition, through which the company is connecting 30 schools across Malawi, Burundi, Zambia, and Zimbabwe by the end of 2026. The initiative, developed in cooperation with the ITU Telecommunication Development Bureau, aims to expand access to digital education and online resources for an estimated 20,000 to 30,000 students and teachers in underserved and remote communities. Through SES’s solutions, the coalition has given students and educators access to online learning platforms, teacher-training resources and collaboration tools. These resources help schools strengthen digital skills and expand learning opportunities to allow students better participate in the futu

Regnology and ActiveViam Partner to Bring the Same Granular, Explainable Risk Intelligence to Banks and Their Supervisors16.11.2026 09:00:00 CET | Press release

ActiveViam’s Atoti analytics will extend from Regnology Risk Hub to Regnology Supervisory Hub, so the regulated and their regulators can ask their own questions of granular data Regnology, a leading global technology provider at the intersection of regulatory reporting, risk management, finance, and supervisory technology, today announced a strategic partnership with ActiveViam, the provider of Atoti, the AI-native enterprise risk intelligence platform for capital markets. The partnership embeds Atoti as the real-time risk aggregation and analytics engine in Regnology Risk Hub, and will extend it to supervisory authorities through Regnology Supervisory Hub. Regnology is the only provider whose offering serves both the regulated and their regulators, with more than 15,000 financial institutions and more than 100 authorities as clients. Markets and depositors now move within days, and the questions that follow rarely fit a predefined report. During the 2023 market turmoil, supervisors fa

Don’t Let Europe’s Nicotine Black Market Go Unchecked16.11.2026 08:06:00 CET | Press release

Crime Stoppers International asks the public to report illegal vapes and nicotine pouches as organised crime cashes in across Europe. Launched on the UN day against transnational organised crime: the criminals selling black market vapes and nicotine pouches also traffic fake medicine, illicit drugs and weapons. On the UN International Day against Transnational Organised Crime, Crime Stoppers International (CSI) launched Don’t let it go unchecked, a campaign asking the public to help break Europe’s black market in vapes and nicotine pouches by reporting illegal sellers anonymously. This matters more than ever. Illegal vapes and nicotine pouches are flooding into Europe. The sellers don’t care how they’re made or who buys them, and don’t pay taxes. Nobody knows who's behind them, except the criminal networks cashing in. The illegal trade in nicotine products is funding the same criminal networks that traffic fake medicine, illicit drugs and weapons, and putting untested products into the

Sofinnova Partners Closes €725M Crossover II Fund16.11.2026 08:00:00 CET | Press release

Backing late-stage life sciences companies through to clinical development, global expansion and commercialization. Positions Sofinnova to support approximately 15 high-growth companies, primarily in Europe, with selective investments in the U.S. and other markets. Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Crossover II at €725 million ($815 million USD). The fund exceeded its original target, reflecting growing confidence in Sofinnova’s strategy of backing late-stage life sciences companies with the potential to become global leaders. Sofinnova Crossover II will focus primarily on European clinical-stage biopharma and medtech companies seeking capital to advance toward commercialization. It will also invest in best-in-class companies in the United States and other international markets. Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye